GleamWall
中文EN

SANA Sana Biotechnology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1770121 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY36.3%
TTM EPS YoY45.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-79.5%
ROA-36.8%
ROIC (approx.)-109.1%
Asset turnover—

Leverage & solvency

Liabilities / assets52.0%
Debt / equity0.00x
Current ratio1.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$131.98M$215.67M
SG&A expense$44.30M$64.04M
Operating income-$250.32M-$272.72M
Income tax$0—
Net income-$244.17M-$266.76M
EBITDA-$237.52M-$257.22M
EPS (basic)-0.96-1.16
EPS (diluted)-0.96-1.16
Weighted avg. shares (diluted)253.23M230.89M
Balance sheet
Cash & equivalents$71.87M$131.40M
Short-term investments$66.51M$24.93M
Current assets$148.68M$160.81M
PP&E, net$26.91M$77.31M
Goodwill$140.63M$140.63M
Intangibles$59.20M$59.20M
Total assets$416.89M$501.02M
Current liabilities$78.73M$45.43M
Total liabilities$256.01M$250.52M
Shareholders' equity$160.88M$250.50M
Shares outstanding266.73M223.92M
Cash flow statement
Operating cash flow-$143.83M-$223.15M
Capital expenditure$938,000$33.43M
Free cash flow-$144.77M-$256.58M
Investing cash flow-$40.24M$17.45M
Financing cash flow$128.73M$199.75M
Depreciation & amortization$12.80M$15.50M
Stock-based compensation$25.46M$37.68M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.